M. Bibby

发表

The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.

S. Picksley, D. Dart, P. Cooper, 2004, International journal of oncology.

50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

M. Bibby, M. Suggitt, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: Subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials

R. Rees, P. Cooper, M. Bibby, 1999, Clinical & Experimental Metastasis.

Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.

M. Bibby, M C Bibby, 2004, European journal of cancer.

Preliminary experimental anticancer activity of cecropins.

M. Bibby, A. Moore, D. Devine, 1994, Peptide research.

A preclinical pharmacokinetic study of the bioreductive drug AQ4N.

M. Bibby, P. Loadman, D. Swaine, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomasin vivo andin vitro; use of liposomes

I. Fichtner, J. Double, M. Bibby, 2004, Breast Cancer Research and Treatment.

Agent Activated by Membrane-Type Matrix Metalloproteinases Development of a Novel Tumor-Targeted Vascular Disrupting

M. Bibby, P. Loadman, J. Atkinson, 2011 .

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

M. Bibby, P. Loadman, J. Atkinson, 2010, Cancer research.

Cancer esearch apeutics , Targets , and Chemical Biology elopment of a Novel Tumor-Targeted Vascular upting Agent Activated by Membrane-Type R rix Metalloproteinases

M. Bibby, L. Patterson, D. Edwards, 2010 .

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

M. Bibby, G. Pettit, K. Grosios, 1999, British Journal of Cancer.

Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.

M. Bibby, P. Loadman, D. Swaine, 2000, Anticancer research.

Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.

P. Cooper, M. Bibby, S. Shnyder, 2002, Anticancer research.

Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate

P. Cooper, M. Bibby, P. Loadman, 2004, Clinical Cancer Research.

EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.

J. Double, M. Bibby, J. Collard, 1995, British Journal of Cancer.

Drug Development in Europe

D. Lacombe, M. Bibby, S. Burtles, 2004 .

In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.

M. Bibby, M. Stevens, T. Bradshaw, 2004, Molecular cancer therapeutics.

Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs.

M. Bibby, R. Wheelhouse, A. Nicolaou, 2006, European journal of medicinal chemistry.

Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice

M. Bibby, G. Margison, J. Rafferty, 1999, British Journal of Cancer.

Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).

M. Bibby, M. Tisdale, H. Hussey, 1996, British Journal of Cancer.

Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model.

P. Cooper, M. Bibby, S. Shnyder, 2008, Journal of natural products.

Antimicrobial activity of cecropins.

M. Bibby, A. Moore, D. Devine, 1996, The Journal of antimicrobial chemotherapy.

Therapeutic index: a vital component in selection of anticancer agents for clinical trial.

J. Double, M. Bibby, 1989, Journal of the National Cancer Institute.

Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs.

P. Cooper, J. Double, M. Bibby, 1998, Cancer research.

Regulation of homocysteine metabolism in a mouse colon tumour model.

M. Bibby, A. Nicolaou, A. Blackburn, 2001 .

The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours.

J. Cox, M. Bibby, P. K. Quinn, 1992, British Journal of Cancer.

Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.

T. Andresen, M. Bibby, K. Jørgensen, 2004, Molecular cancer therapeutics.

Role of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents.

M. Bibby, G. Margison, T. G. Baker, 2000, Journal of reproduction and fertility.

Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9

M. Bibby, P. Loadman, R. Phillips, 2002, British journal of pharmacology.

Factors affecting the in vitro dissolution of cobalt oxide.

J. Double, M. Bibby, R. Phillips, 1992, British Journal of Cancer.

Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity.

J. Double, M. Bibby, D. Poyner, 2002, Biochemical pharmacology.

Heparin Octasaccharides Inhibit Angiogenesis In vivo

G. Jayson, J. Double, M. Bibby, 2005, Clinical Cancer Research.

Cytochrome P 450 1 B 1 ( CYP 1 B 1 ) Is Overexpressed in Human Colon Adenocarcinomas Relative to Normal Colon : Implications for Drug Development 1

J. Double, M. Bibby, P. Loadman, 2003 .

Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.

J. Double, M. Bibby, R. Phillips, 1991, British Journal of Cancer.

An introduction to telomeres and telomerase

M. Bibby, 2003, Methods in molecular biology.

Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo

P. Cooper, J. Double, M. Bibby, 2003, British Journal of Cancer.

Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action.

M. Bibby, P. Loadman, M. Suggitt, 2003, Teratogenesis, carcinogenesis, and mutagenesis.

Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.

J. Double, M. Bibby, P. Loadman, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals.

R. A. Brennan, J. Double, M. Bibby, 1987, Journal of the National Cancer Institute.

A study of changes in uterine mast cells during early pregnancy in the rat.

M. Bibby, J. M. Brandon, 1979, Biology of reproduction.

Development of a novel tumor-targeted vascular disrupting agent activated by MT-MMPs

M. Bibby, J. Atkinson, L. Patterson, 2010 .

ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour

M. Bibby, P. Loadman, J. Masters, 1996, Cancer Chemotherapy and Pharmacology.

A critical appraisal of the predictive value of in vitro chemosensitivity assays.

J. Double, M. Bibby, R. Phillips, 1990, Journal of the National Cancer Institute.

The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.

P. Cooper, M. Bibby, M. Suggitt, 2006, International journal of oncology.

Reducing the cost of screening novel agents using the hollow fibre assay.

P. Cooper, M. Bibby, A. Scally, 2006, Anticancer research.

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

M. Bibby, B. Hill, B. Hill, 2001, British Journal of Cancer.

Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice.

D. Kerr, J. Double, M. Bibby, 1989, Cancer research.

Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.

J. Double, M. Bibby, P. Loadman, 1989, Journal of the National Cancer Institute.

Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).

J. Double, M. Bibby, P. Loadman, 1988, British Journal of Cancer.

Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).

J. Double, M. Bibby, P. Loadman, 1987, British Journal of Cancer.

Synthesis and Antitumour Activity of New Derivatives of Flavone‐8‐acetic Acid (FAA). Part 31): 2‐Heteroaryl Derivatives

J. Double, M. Bibby, A. Mathieu, 1998, Archiv der Pharmazie.

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.

J. Double, M. Bibby, A. Matthew, 1995, British Journal of Cancer.

Flavone acetic acid: is vascular shutdown the crucial mechanism of action.

J. Double, M. Bibby, R. Phillips, 1991, International journal of radiation biology.

In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine.

M. Bibby, K. M. Nicholson, R. Phillips, 2002, European journal of cancer.

Expression of MMP-10 in Human Transitional-Cell Carcinoma of the Bladder

M. Bibby, P. Loadman, B. Naylor, 2014 .

Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.

M. Bibby, P. Loadman, B. Naylor, 2005, Urology.

MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.

M. Bibby, P. Loadman, A. Mearns, 2004, Neoplasia.

Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512)

J. Double, M. Bibby, R. Phillips, 1989, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of PK 1 and Doxorubicin in Experimental Colon Tumor Models with Differing Responses to PK 11

J. Double, M. Bibby, P. Loadman, 1999 .

Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.

M. Bibby, P. Loadman, R. Phillips, 2000, Biochemical pharmacology.

Flavone acetic acid--from laboratory to clinic and back.

J. Double, M. Bibby, M. Bibby, 1993, Anti-cancer drugs.

Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.

J. Double, M. Bibby, P. Loadman, 1986, British Journal of Cancer.

In-vitro cytotoxic activities of the major bromophenols of the red alga Polysiphonia lanosa and some novel synthetic isomers.

M. Bibby, R. Wheelhouse, P. Linley, 2004, Journal of natural products.

Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.

E. Sausville, P. Cooper, J. Double, 2002, Molecular cancer therapeutics.

Synthesis, mechanism of action, and biological evaluation of mitosenes.

D. Reinhoudt, W. Verboom, J. Double, 1989, Journal of medicinal chemistry.

SYNTHESIS AND ANTI-TUMOUR ACTIVITY OF 6-METHYL DERIVATIVES OF FLAVONE-8-ACETIC ACID (FAA)

Shiv k. Sharma, J. Double, M. Bibby, 1994 .

EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.

J. Double, M. Bibby, H. Fiebig, 1993, European journal of cancer.

Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311

M. Bibby, A. Burger, J. Double, 1999, British Journal of Cancer.

Evaluation of Some Egyptian Plant Species for in vitro Antimycobacterial and Cytotoxic Activities

M. Bibby, C. Wright, N. Shoeib, 2003 .

Evaluation of the anti-tumour action and acute toxicity of kosins from Hagenia abyssinica.

A. Fell, M. Bibby, P. Linley, 1992, Journal of pharmaceutical and biomedical analysis.

The uptake of radio-active glucose in vivo and in vitro by the metacercaria of Diplostomum phoxini (Faust) and its conversion to glycogen

M. Bibby, G. Rees, 2004, Zeitschrift für Parasitenkunde.

The relationship between the in vitro chemosensitivity of tumor cells and tumor response in vivo in an experimental tumor model.

J. Double, M. Bibby, P. Loadman, 1991, International journal of cell cloning.

Characterization of the Hollow Fiber Assay for the Determination of Microtubule Disruption In vivo

M. Bibby, M. Suggitt, George R Pettit, 2004, Clinical Cancer Research.

Seasonal Variation in Bromophenol Content of Polysiphonia lanosa

M. Bibby, P. Linley, G. Blunden, 2006 .

Temporal evaluation of methionine synthase and related metabolites in the MAC15A mouse adenocarcinoma animal model

M. Bibby, M. Lucock, A. Nicolaou, 2004, International journal of cancer.

The delivery of antisense therapeutics.

J. Double, M. Bibby, M. Hughes, 2000, Advanced drug delivery reviews.

Synthesis and Antitumour Activity of New Derivatives of Flavone‐8‐acetic Acid (FAA). Part 4 1) : Variation of the Basic Structure

P. Cooper, J. Double, M. Bibby, 2000, Archiv der Pharmazie.

Potentiation of testicular cytotoxicity by the alkyltransferase inhibitor O6 benzylguanine and the 5-fluorouracil/N-(2-chloroethyl)-N-nitrosourea molecular combination, B.4152.

M. Bibby, T. G. Baker, M. Thompson, 1996, Reproductive toxicology.

Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours

A. Howell, W. Ryder, G. Margison, 2002, British Journal of Cancer.

Synthesis and Antitumor Activity of New Derivatives of Flavone‐8‐acetic Acid (FAA). Part 4. Variation of the Basic Structure.

P. Cooper, J. Double, M. Bibby, 2000 .

Synthesis and Antitumour Activity of New Derivatives of Flavone‐8‐acetic Acid (FAA). Part 2 : Ring‐Substituted Derivatives

J. Double, M. Bibby, R. Aitken, 1997, Archiv der Pharmazie.

Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.

J. Double, M. Bibby, P. Dumont, 1989, Anti-cancer drug design.

Nucleoside analogues. 13. The effect on anti-tumour activity of varying the uracil 5-substituent and the point of attachment (N1 or N3) of the uracil moiety in seco-nucleoside nitrosoureas.

J. Double, M. Bibby, P. Dumont, 1993, Anti-cancer drug design.

Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1).

M. Bibby, R. Pettit, E. Hamel, 2005, Journal of natural products.

Making the most of rodent tumour systems in cancer drug discovery

M. Bibby, 1999, British Journal of Cancer.

Quantitative Angiogenesis Assays in vivo – A Review

G. Jayson, J. Double, M. Bibby, 2004, Angiogenesis.

Synthesis and cytotoxicity of shikimate analogues. Structure:activity studies based on 1-crotonyloxymethyl-3R,4R,5R-trihydroxycyclohex-2-enone.

J. Double, M. Bibby, K. Douglas, 1992, Anti-cancer drug design.

Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice

J. Double, M. Bibby, R. J. Hambly, 1997, Breast Cancer Research and Treatment.

MORPHOLOGICAL CHANGES AND CYTOKINE GENE EXPRESSION IN TUMOR XENOGRAFTS FOLLOWING TREATMENT WITH THE ALKYLPHOSPHOCHOLINES HEXADECYLPHOSPHOCHOLINE AND P ERIFOSINE

M. Bibby, O. Safa, S. Parkin, 1998 .

The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors.

S. Burchill, M. Bibby, E. M. Bridges., 2006, The Journal of pediatrics.

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

I. Stratford, J. Double, M. Bibby, 2000, British Journal of Cancer.

Flavone acetic acid--an interesting novel therapeutic agent or just another disappointment?

M. Bibby, 1991, British Journal of Cancer.

Telomeres and Telomerase. Ciba Foundation Symposium 211

M. Bibby, 1999, British Journal of Cancer.

Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.

I. Fichtner, M. Bibby, M. Becker, 2004, European journal of cancer.

THE SPECIFICITY OF EARLY CHANGES IN THE SKIN DURING CARCINOGENESIS

M. Bibby, 1981, The British journal of dermatology.

Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.

I. Fichtner, J. Double, M. Bibby, 2004, Anticancer research.

Pharmacokinetic Drug Interactions with Anticancer Drugs

M. Bibby, P. Loadman, 1994, Clinical pharmacokinetics.

The ultrastructure of the epidermis and associated structures in the metacercaria cercaria and sporocyst of Diplostomum phoxini (Faust, 1918)

M. Bibby, G. Rees, 2004, Zeitschrift für Parasitenkunde.

Phytochemistry and preliminary biological evaluation of Cyathostemma argenteum, a malaysian plant used traditionally for the treatment of breast cancer

I. Scowen, P. Cooper, M. Bibby, 2004, Phytotherapy research : PTR.

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.

M. Bibby, A. Burger, J. Konopa, 1996, British Journal of Cancer.

Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.

P. Cooper, M. Bibby, S. Shnyder, 2010, Molecular medicine reports.

Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.

P. Cooper, M. Bibby, S. Shnyder, 2007, International journal of oncology.

Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy.

J. Double, M. Bibby, A. Burger, 1997, British Journal of Cancer.

An introduction to telomeres and telomerase.

M. Bibby, 2003, Molecular Biotechnology.

Differentiation and definition of vascular-targeted therapies.

P. LoRusso, A. Dicker, M. Bibby, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.

P. Cooper, M. Bibby, G. Pettit, 2002, Anticancer research.

Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids.

M. Bibby, K. M. Nicholson, R. Phillips, 1997, European journal of cancer.

IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.

M. Bibby, O. Safa, S. Parkin, 1997, Biochemical Society Transactions.

Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts.

M. Bibby, A. Matthew, O. Safa, 1997, Anticancer Research.

The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.

J. Double, M. Bibby, T. G. Baker, 1988, British Journal of Cancer.

Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development.

J. Double, M. Bibby, P. Loadman, 2003, Molecular cancer therapeutics.

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

P. Cooper, M. Bibby, J. Hasan, 2005, Anticancer research.

C-type and intracisternal A-type virus particles during epidermal carcinogenesis by tobacco smoke condensate in BALB/c mice.

M. Bibby, G. M. Smith, 1977, British Journal of Cancer.

Increase in type A virus particles induced in BALB/c mouse epidermis during chemical carcinogenesis.

M. Bibby, G. M. Smith, 1975, British Journal of Cancer.

Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.

J. Double, M. Bibby, M. Mughal, 1981, British Journal of Cancer.

Characterisation and chemosensitivity of a well-differentiated murine transplantable adenocarcinoma of the colon.

J. Double, M. Bibby, 1983, British Journal of Cancer.

DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas.

P. Workman, M. Walton, J. Double, 1992, European journal of cancer.

Expression of HIF-1alpha and Glut-1 in human bladder cancer.

M. Bibby, R. Phillips, T. Shah, 2005, Oncology reports.

Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate

E. Sausville, M. Bibby, H. Fiebig, 2013, Cancer Chemotherapy and Pharmacology.

High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide.

M. A. Graham, M. Bibby, P. Loadman, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Potentiation of EO9 anti-tumour activity by hydralazine.

J. Double, M. Bibby, P. Loadman, 1993, European journal of cancer.

Telomerase activity in malignant and benign bladder conditions.

M. Bibby, G. Flannigan, T. Shah, 1998, International journal of molecular medicine.

Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model

M. Bibby, P. Loadman, J. Double, 1992, Investigational New Drugs.

Population biology of the helminth parasites of Phoxinus phoxinus (L.), the minnow, in a Cardiganshire lake

M. Bibby, 1972 .

Use of the hollow fiber assay for the evaluation of DNA damaging agents.

P. Cooper, M. Bibby, L. Patterson, 2011, Journal of pharmacological and toxicological methods.

Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice

J. Double, M. Bibby, P. Loadman, 1998, Cancer Chemotherapy and Pharmacology.

In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans.

J. Brown, J. Double, M. Bibby, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.

J. Double, M. Bibby, P. Loadman, 1992, British Journal of Cancer.

5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice

M. Bibby, S. Hill, 2004, Cancer Chemotherapy and Pharmacology.

Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies.

J. Double, M. Bibby, S. Cowen, 1995, Acta oncologica.

Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours.

J. Double, M. Bibby, C. M. Morris, 1988, European journal of cancer & clinical oncology.

Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.

J. Double, M. Bibby, P. Loadman, 1988, European journal of cancer & clinical oncology.

Potential of AG in the treatment of breast cancer

M. Bibby, P. Loadman, J. Stanslas, 2001 .

Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours

M. Bibby, R. Phillips, J. Double, 2004, Cancer Chemotherapy and Pharmacology.

Activity of N-[N′-(2-chloroethyl)-N′-nitrosocarbamoyl]-alanine and derivatives against transplantable adenocarcinomata of the mouse colon (MAC)

J. Double, M. Bibby, 2004, Journal of Cancer Research and Clinical Oncology.

Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma.

M. Bibby, S. Hill, L. A. Pollard, 1992, Anticancer research.

Pre-clinical evaluation of a novel chloroethylating agent, Clomesone.

M. Bibby, P. Loadman, R. Phillips, 1993, British Journal of Cancer.

In vitro and in vivo responses of a panel of murine colon tumours to TCNU: a positive correlation.

J. Double, M. Bibby, R. Phillips, 1988, European journal of cancer & clinical oncology.

ANTI-TUMOUR ACTIVITY AND BONE MARROW TOXICITY OF CLOMESONE 443 Pharmacokinetic studies

M. Bibby, P. Loadman, R. Phillips, 2007 .

The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells.

M. Bibby, S. Patel, S. Parkin, 1997, Anticancer research.

Quantitative methods for assessing the effects of some anticancer drugs on mouse spermatogenesis.

M. Bibby, T. G. Baker, I. Wahed, 1987, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.

P. Cooper, M. Bibby, S. Shnyder, 2003, Anticancer research.

Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.

J. Double, M. Bibby, P. Dumont, 1989, Anti-Cancer Drug Design.

Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.

J. Double, M. Bibby, P. Dumont, 1989, Anti-Cancer Drug Design.

Synthesis and Antitumor Activity of New Derivatives of Flavone-8- acetic Acid (FAA). Part 2. Ring-Substituted Derivatives

J. Double, M. Bibby, R. Aitken, 1997 .

Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens.

J. Double, M. Bibby, P. Loadman, 1985, Journal of chromatography.

Thio TEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80

A. Mundy, M. Bibby, P. Loadman, 2004, Cancer Chemotherapy and Pharmacology.

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

M. Bibby, P. Loadman, J. Atkinson, 2010, Cancer research.

Evaluation of the cytotoxicity of the indoloquinone eo9 in a human colon adenocarcinoma model.

M. Bibby, R. Phillips, B. Cronin, 1993, International Journal of Oncology.